Huang ChuanXin, Melnick Ari
Shanghai Institute of Immunology & Department of Immunobiology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA.
Sci China Life Sci. 2015 Dec;58(12):1226-32. doi: 10.1007/s11427-015-4919-z. Epub 2015 Nov 14.
The transcriptional repressor B cell lymphoma 6 (BCL6) controls a large transcriptional network that is required for the formation and maintenance of germinal centers (GC). GC B cells represent the normal counterpart of most human B-cell lymphomas, which are often characterized by deregulated BCL6 expression or BCL6-mediated pathways. BCL6 suppresses gene transcription largely through recruitment of its co-repressors through its distinct repression domain. Understanding the precise biological roles of each repression domain in normal and malignant B cells is helpful for development of targeted inhibition of BCL6 functions that is emerging as the basis for design of anti-lymphoma therapies. This review focuses on recent progress in the molecular mechanisms of action of BCL6 in B cells and discusses remaining unresolved questions related to how these mechanisms are linked to normal and malignant B cell development.
转录抑制因子B细胞淋巴瘤6(BCL6)控制着一个大型转录网络,该网络对于生发中心(GC)的形成和维持至关重要。GC B细胞是大多数人类B细胞淋巴瘤的正常对应物,这些淋巴瘤通常以BCL6表达失调或BCL6介导的信号通路为特征。BCL6主要通过其独特的抑制结构域募集共抑制因子来抑制基因转录。了解每个抑制结构域在正常和恶性B细胞中的精确生物学作用,有助于开发靶向抑制BCL6功能的方法,这正成为抗淋巴瘤治疗设计的基础。本综述重点介绍了BCL6在B细胞中作用分子机制的最新进展,并讨论了与这些机制如何与正常和恶性B细胞发育相关的尚未解决的问题。